Since ULBP1 plays a role in the recognition of target cells [91] and the combination of ICAM1 and lymphocyte function-associated antigen 1 (LFA-1) enhances immune cells to kill the target cells [92], targeting AXL is beneficial to the formation of anti-tumor microenvironment and enhances the treatment response. This evidence concerns the gene AXL and neoplasm.